Clinical and molecular characteristics of patients
| Variable | Total |
| Age (n=74) (years) | |
| (mean, min-max) | 63 (27–83) |
| Gender | |
| Male:female | 64 (86%):10 (14%) |
| Aetiology (including 12 patients with ≥2 aetiologies) | |
| Alcohol | 20 (27%) |
| Hepatitis B | 20 (27%) |
| Hepatitis C | 20 (27%) |
| Haemochromatosis | 7 (9%) |
| Metabolic syndrome | 12 (16%) |
| Without known aetiology | 6 (8%) |
| Tumour features (n=74) | |
| Tumour size (mm) (mean, min-max) | 71 (11–190) |
| Macrovascular and/or microvascular invasion | 39 (53%) |
| Edmondson grading (n=74) | |
| Edmondson I–II | 30 (41%) |
| Edmondson III–IV | 44 (59%) |
| Differentiation WHO (n=74) | |
| Good | 13 (18%) |
| Medium | 49 (66%) |
| Weak | 12 (16%) |
| Non-tumorous liver: fibrosis according to METAVIR (n=73) | |
| F0–F1 | 20 (27%) |
| F2–F3 | 26 (36%) |
| F4 | 27 (37%) |
| G1G6 classification (n=70) | |
| G1–G3 | 28 (40%) |
| G4–G5 | 42 (60%) |
| TERT mutations (n=72) | |
| Mutated | 51 (71%) |
| Non-mutated | 21 (29%) |
| CTNNB1 mutations (n=71) | |
| Mutated | 32 (45%) |
| Non-mutated | 39 (55%) |
| TP53 mutations (n=72) | |
| Mutated | 23 (32%) |
| Non-mutated | 49 (68%) |
| ALBUMIN mutations (n=64) | |
| Mutated | 9 (14%) |
| Non-mutated | 55 (86%) |
| AXIN1 mutations (n=71) | |
| Mutated | 4 (5.6%) |
| Non-mutated | 67 (94.4%) |
| ARID1A mutations (n=71) | |
| Mutated | 8 (11.3%) |
| Non-mutated | 63 (88.7%) |
| ARID2 mutations (n=71) | |
| Mutated | 3 (4.2%) |
| Non-mutated | 68 (95.8%) |